Arthneeti
Latest: IOL Chemicals Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
IC

IOL Chemicals

Q1 FY27Pharmaceuticals & Biotechnology

IOL Chemicals Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹174
Market cap₹5.0K Cr
P/E28.2
Updated25 Aug 2026
Read3 min read

What the Q1 FY27 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

The short version

FY27 revenue growth guidance: 15% to 20% - FY28 revenue growth plan: Approximately 15% to 20% - EBITDA margin for FY27 expected in range of 14% to 15%, with potential slight improvement in FY28 (1 FY27 Revenue Growth Guidance: 15% to 20% increase expected.

From IOL Chemicals's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • FY27 revenue growth guidance: 15% to 20%
  • FY28 revenue growth plan: Approximately 15% to 20%
  • EBITDA margin for FY27 expected in range of 14% to 15%, with potential slight improvement in FY28 (15% to 17%)
  • Growth driven by better capacity utilization, improved product mix, operational efficiencies, and increased exports
  • Continued expansion in non-ibuprofen API portfolio to support broad-based growth
  • Targeting non-ibuprofen products to contribute around 50%-55% of API segment by FY29
  • Export contribution expected to be around 25% to 30% of revenue, targeting ~30% in near term

2 more points from IOL Chemicals's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what IOL Chemicals said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • The company plans a capex of approximately INR 200-250 crores per year.
  • Around 60% of the annual capex is directed towards expansion and new product developments.
  • The remaining 40% of capex is for infrastructure improvements, enhancing efficiencies, and cost reduction.
  • The company has a 101-acre land parcel for future expansion; statutory permissions are underway.
  • New projects on the 101-acre land are expected beyond the current fiscal year (not in FY27).
  • R&D is active with ongoing projects; they will share more when proof-of-concepts are ready.

2 more points from IOL Chemicals's call on capex

Create a free account to keep reading this call

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what IOL Chemicals said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • The company has reasonable visibility into its order book for the coming quarter, providing confidence in the overall guidance for the year.
  • Strong demand and healthy order inflow are expected to sustain growth this year.
  • Export agreements include quantities with specific customers, and some variability quarter-to-quarter in dispatches can cause minor fluctuations in export numbers.
  • Company maintains a disciplined approach to capital allocation and investments based on long-term returns, implying ongoing order inflow aligned with capacity expansions and product mix improvements.

IOL Chemicals — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹795 Cr, net profit ₹65 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What IOL Chemicals's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • KRM Ayurveda (Q1 FY27)

    Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r

  • Balaxi Pharma (Q1 FY27)

    Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr

  • Sanjiv.Parant. (Q1 FY27)

    Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani

  • Natural Capsules (Q1 FY27)

    Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharma.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

IOL Chemicals and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were IOL Chemicals Q1 FY27 results?

FY27 revenue growth guidance: 15% to 20% - FY28 revenue growth plan: Approximately 15% to 20% - EBITDA margin for FY27 expected in range of 14% to 15%, with potential slight improvement in FY28 (1 FY27 Revenue Growth Guidance: 15% to 20% increase expected.

What is IOL Chemicals share price analysis?

IOL Chemicals currently shows a below-average growth signal. The stock trades at a P/E of 28.2 with a market cap of ₹4,976 Cr. Investors should review the full earnings analysis for detailed insights.

Is IOL Chemicals planning capital expenditure?

The company plans a capex of approximately INR 200-250 crores per year.

Keep IOL Chemicals on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.